{"id":"W4407762907","doi":"10.1016/j.ijgc.2025.101701","title":"Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Carboplatin; Paclitaxel; Endometrial cancer; Oncology; Internal medicine; Urology; Gynecology; Cancer; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000472979,0.0001455562,0.0004497238,0.0001380184,0.0001217804,0.0004386448,0.0001686174,0.0002417767,0.0006422499],"category_scores_gemma":[0.0008642219,0.00007766191,0.0005654753,0.0002165052,0.0001247836,0.0003734925,0.0001647855,0.0005591058,0.00007778598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004815625,"about_ca_system_score_gemma":0.0003753745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001445323,"about_ca_topic_score_gemma":0.004267284,"domain_scores_codex":[0.9998223,0.00005821653,0.00001443229,0.0000321654,0.00003260047,0.00004026373],"domain_scores_gemma":[0.9996705,0.00007764989,0.0001384369,0.00001438311,0.00001030828,0.00008865156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.150187,0.00301516,0.6119934,0.0005449431,0.003394309,0.0006287601,0.0002928172,0.001820105,0.0058552,0.0004537762,0.003233814,0.2185807],"study_design_scores_gemma":[0.008907118,0.02819239,0.9503415,0.0001672769,0.002371747,0.001263854,0.0004576765,0.003335978,0.001317635,0.0004146956,0.003195591,0.00003460811],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967865,0.002347515,0.00004458087,0.0001111845,0.00001910775,0.00001472165,0.0002336675,0.000003960061,0.0004386769],"genre_scores_gemma":[0.9984028,0.0007992044,0.00008439743,0.0001251707,0.00001887978,0.00001243086,0.0004114507,0.000001396523,0.0001442198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001445323,"threshold_uncertainty_score":0.003493965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0606368878569673,"score_gpt":0.3927037686228137,"score_spread":0.3320668807658464,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}